Dr Chukwuemeka Onyewu, MD | |
8720 Georgia Ave, Suite 706, Silver Spring, MD 20910-3638 | |
(301) 589-2015 | |
(301) 589-2007 |
Full Name | Dr Chukwuemeka Onyewu |
---|---|
Gender | Male |
Speciality | Plastic And Reconstructive Surgery |
Experience | 34 Years |
Location | 8720 Georgia Ave, Silver Spring, Maryland |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1760420764 | NPI | - | NPPES |
06370001 | Other | DC | BLUE CROSS BLUE SHIELD |
12206 | Other | DC | DC CHARTERED |
2206407 | Other | MD | UNITED HEALTH CARE |
2573303 | Other | MD | AETNA |
3127603 | Other | MD | OPTIMUM CHOICE/MAMSI |
59679 | Other | MD | AMERIGROUP |
64131801 | Other | MD | MD BCBS |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208200000X | Plastic Surgery | D0050971 (Maryland) | Primary |
Entity Name | Chukwuemeka Onyewu Md Pc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1972898385 PECOS PAC ID: 3779752704 Enrollment ID: O20110809000518 |
News Archive
When scientists need to understand the effects of new infant formula ingredients on brain development, it's rarely possible for them to carry out initial safety studies with human subjects.
Ceregene, a biopharmaceutical company, announced today that it is progressing with enrollment and dosing in its CERE-120 Phase 2b multi-center, sham-surgery, double-blinded controlled trial in Parkinson's disease.
A $6 million grant from the National Heart, Lung and Blood Institute (NHLBI) has funded the creation of ORBIT: Obesity Related Behavioral Intervention Trials to focus on reducing obesity and obesity-related deaths in New York City's African-American and Latino communities.
Findings from one of the largest-ever imaging studies of depression indicate that a structural difference in the brain - a thinning of the right hemisphere - appears to be linked to a higher risk for depression, according to new research at Columbia University Medical Center and the New York State Psychiatric Institute.
Rosetta Genomics, Ltd., a leading developer and provider of microRNA-based molecular diagnostic tests, announced today the receipt of a new notice of allowance from the United States Patent and Trademark Office ("USPTO") for U.S. patent application 11/418,870, including claims related to Sanger hsa-miR-451. miR-451 is used in the Company's miRview™ mets test, which accurately identifies the primary tumor site in patients with metastatic cancer and Cancer of Unknown Primary (CUP).
› Verified 6 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Chukwuemeka Onyewu, MD 17041 Barn Ridge Dr, Silver Spring, MD 20906-1108 Ph: (301) 570-8102 | Dr Chukwuemeka Onyewu, MD 8720 Georgia Ave, Suite 706, Silver Spring, MD 20910-3638 Ph: (301) 589-2015 |
News Archive
When scientists need to understand the effects of new infant formula ingredients on brain development, it's rarely possible for them to carry out initial safety studies with human subjects.
Ceregene, a biopharmaceutical company, announced today that it is progressing with enrollment and dosing in its CERE-120 Phase 2b multi-center, sham-surgery, double-blinded controlled trial in Parkinson's disease.
A $6 million grant from the National Heart, Lung and Blood Institute (NHLBI) has funded the creation of ORBIT: Obesity Related Behavioral Intervention Trials to focus on reducing obesity and obesity-related deaths in New York City's African-American and Latino communities.
Findings from one of the largest-ever imaging studies of depression indicate that a structural difference in the brain - a thinning of the right hemisphere - appears to be linked to a higher risk for depression, according to new research at Columbia University Medical Center and the New York State Psychiatric Institute.
Rosetta Genomics, Ltd., a leading developer and provider of microRNA-based molecular diagnostic tests, announced today the receipt of a new notice of allowance from the United States Patent and Trademark Office ("USPTO") for U.S. patent application 11/418,870, including claims related to Sanger hsa-miR-451. miR-451 is used in the Company's miRview™ mets test, which accurately identifies the primary tumor site in patients with metastatic cancer and Cancer of Unknown Primary (CUP).
› Verified 6 days ago
Allan C Smith, M.D. Plastic Surgery Medicare: Not Enrolled in Medicare Practice Location: 13209 Banbury Pl, Silver Spring, MD 20904 Phone: 301-384-7371 |